Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Jair Bar's publication output changed over time?
ScholarIQpublication output · 2018–2024
Output grew200% over the shown period — from 1 works in 2018 to 3 in 2024.
1
2
2
1
2
3
201820192020202120222024
What are the most-cited papers on Jair Bar?
ScholarIQmost cited works
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Deborah Nejman, Ilana Livyatan, Garold Fuks, Nancy Gavert, Yaara Zwang, Leore T. Geller, Aviva Rotter-Maskowitz, Roi Weiser, Giuseppe Mallel, Elinor Gigi, Arnon Meltser, Gavin M. Douglas, Iris Kamer, Vancheswaran Gopalakrishnan, Tali Dadosh, Smadar Levin‐Zaidman, Sofia Avnet, Tehila Atlan, Zachary A. Cooper, Reetakshi Arora, Alexandria P. Cogdill, Md Abdul Wadud Khan, Gabriel O Ologun, Yuval Bussi, Adina Weinberger, Maya Lotan‐Pompan, Ofra Golani, Gili Perry, Merav Rokah, Keren Bahar‐Shany, Elisa A. Rozeman, Christian U. Blank, Anat Ronai, Ron Shaoul, Amnon Amit, Tatiana Dorfman, Ran Kremer, Zvi R. Cohen, Sagi Harnof, Tali Siegal, Einav Yehuda‐Shnaidman, Einav Nili Gal‐Yam, Hagit Shapira, Nicola Baldini, Morgan G. I. Langille, Alon Ben‐Nun, Bella Kaufman, Aviram Nissan, Talia Golan, Maya Dadiani, Keren Levanon, Jair Bar, Shlomit Yust‐Katz, Iris Barshack, Daniel S. Peeper, Dan J. Raz, Eran Segal, Jennifer A. Wargo, Judith Sandbank, Noam Shental, Ravid Straussman
Science. 20202,447 CitationsOPEN ACCESS
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz
The Lancet. 20192,246 Citations
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz‐Ares, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Nataliia Voitko, Artem Poltoratskiy, Igor Bondarenko, Yuanbin Chen, Andrzej Każarnowicz, Luis Paz‐Ares, Mustafa Özgüroğlu, Nikolay Conev, Maximilian J. Hochmair, Otto C. Burghuber, Libor Havel, İrfan Çiçin, György Losonczy, В. Моисеенко, Mustafa Erman, Dariusz M. Kowalski, Marek Z. Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Niels Reinmuth, Jun Ho Ji, Maria Amelia Insa Molla, Grygorii Ursol, Anne C. Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Francesco Verderame, Katsuyuki Hotta, Sang‐We Kim, Alexey Smolin, Tuncay Göksel, Shaker R. Dakhil, Jaromı́r Roubec, Krisztina Bogos, Marina Chiara Garassino, Robin Cornelissen, Jong-Seok Lee, M.R. García Campelo, Marta López Brea, Ahmet Alacacıoğlu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, A Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong‐Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, M. Majem Tarruella, David R. Spigel, Krassimir Koynov, Milada Zemanová, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Sławomir Mańdziuk
The Lancet Oncology. 2020700 CitationsOPEN ACCESS
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Nicolas Girard, Jair Bar, Pilar Garrido, Marina Chiara Garassino, Fiona McDonald, F. Mornex, Andrea Riccardo Filippi, Hans J.M. Smit, Solange Peters, John K. Field, Daniel C. Christoph, Anne Sibille, Rainer Fietkau, Vilde Drageset Haakensen, C. Chouaïd, Ben Markman, T. Jeroen N. Hiltermann, Álvaro Taus, W. Sawyer, A. Allen, Pratibha Chander, Muriel Licour, Benjamin Solomon
Journal of Thoracic Oncology. 2022231 CitationsOPEN ACCESS
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, S. Keren, Noa Popovits‐Hadari, Damien Urban, Moshe Mishaeli, Alona Zer, Aaron M. Allen, Natalie Maimon Rabinovich, Ofer Rotem, Teodor Kuznetsov, Tzippy Shochat, Laila C. Roisman, Jair Bar
Journal of Thoracic Oncology. 2018221 CitationsOPEN ACCESS
Related on ScholarIQ
Tel Aviv University
Institution
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Paper
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paper
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Paper
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Paper
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
Paper